US Market News
2週前
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot UlcersJune 25, 2026 8:02 AM
PR Newswire (US) Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU programSARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has accepted the position of Study Chair for the Company's Phase 2a clinical trial evaluating Nu-3 for the treatment of infected diabetic foot ulcers (iDFUs). Dr. Armstrong will also serve as a Scientific Advisor to Lakewood-Amedex Biotherapeutics on the iDFU program. Dr. Armstrong is internationally recognized as one of the world's foremost experts in diabetic foot care, including infection control, wound healing and limb preservation. Throughout his distinguished career, he has authored hundreds of peer-reviewed scientific publications and has helped shape modern approaches to preventing amputations and improving outcomes for patients with diabetes-related complications."We are honored to welcome Dr. Armstrong as Study Chair for our Phase 2a trial and as a Scientific Advisor to Lakewood-Amedex Biotherapeutics," said Thomas Balzer, M.D., Ph.D., Chief Medical Officer of Lakewood-Amedex Biotherapeutics. "Dr. Armstrong's unparalleled experience as both a surgeon and investigator in national and international clinical trials brings an important perspective to the study and our advancement of Bisphosphocin® antimicrobials. We look forward to working closely with him to evaluate the potential of Nu-3 and to further our understanding of how our novel topical antimicrobial therapies may help address persistent challenges in diabetic foot infection management."As Study Chair, Dr. Armstrong will provide scientific leadership and oversight for the Phase 2a study, helping guide the clinical evaluation of Nu-3, Lakewood-Amedex Biotherapeutics' lead Bisphosphocin® antimicrobial candidate. The Phase 2a clinical trial is a proof-of-concept study designed to evaluate the safety and efficacy of topical Nu-3 gel in patients with infected diabetic foot ulcers. The study will evaluate three dose concentrations of Nu-3 (2%, 5% and 10%) and is intended to support advancement into a larger Phase 2b clinical study."Infected diabetic foot ulcers are a significant clinical challenge despite advances in wound care and limb preservation, and antibiotic resistance is a potentially grave concern in this patient population," said Dr. Armstrong. "There remains a substantial need for new therapeutic approaches that can effectively address infection while supporting healing and minimizing the risk of developing resistance. A topical antimicrobial such as Nu-3 fits well with the ongoing evolution of diabetic foot ulcer management, and if clinical studies demonstrate its effectiveness, it has the potential to help address an important treatment gap for patients suffering from these serious infections. I look forward to working with Lakewood-Amedex Biotherapeutics to evaluate the potential of this novel therapeutic approach."About David G. Armstrong, DPM, M.D., Ph.D.
David G. Armstrong, DPM, M.D., Ph.D., is Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC and a globally recognized leader in diabetic foot care, wound healing and limb preservation. His research and clinical work have focused on preventing amputations and improving outcomes for patients with diabetes-related complications. Dr. Armstrong has authored hundreds of peer-reviewed scientific publications and is widely regarded as one of the most influential voices in the field of diabetic foot disease and limb preservation.About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.comMedia Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-world-renowned-expert-david-g-armstrong-md-phd-as-study-chair-for-phase-2a-trial-of-nu-3-in-infected-diabetic-foot-ulcers-302809879.htmlSOURCE Lakewood-Amedex Biotherapeutics Inc. Original: Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
US Market News
3週前
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial InfectionsJune 22, 2026 8:02 AM
PR Newswire (US) New patent enhances global IP footprint and pipeline expansion opportunitiesSARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections. The patent, titled, "Antimicrobial Compounds, Compositions, and Uses Thereof," was issued March 5, 2026, by IP Australia. Lakewood-Amedex Biotherapeutics' intellectual property portfolio is currently comprised of 72 granted patents and 29 pending patents in multiple countries and regions, including the United States, the European Patent Office, China, India, Japan, Mexico, Hong Kong, Republic of Korea, Brazil, United Kingdom, New Zealand, and Australia."This newly issued patent adds to our international intellectual property portfolio covering composition of matter patents for the Bisphosphocin® class of compounds," said Kelvin Cooper, Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "Antimicrobial resistance (AMR) is a global crisis that is directly responsible for more than a six million deaths annually. As we work to deliver innovative antimicrobial solutions designed to tackle the challenges of AMR, our substantial IP foundation enhances our ability to bring solutions to the millions of patients in need, while potentially generating value for our shareholders."About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.ContactInvestor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.comMedia Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-secures-composition-of-matter-patent-protecting-new-bisphosphocin-compounds-being-developed-for-high-need-antimicrobial-infections-302805728.htmlSOURCE Lakewood-Amedex Biotherapeutics Inc. Original: Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
US Market News
1月前
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot UlcersMay 27, 2026 8:02 AM
PR Newswire (US) Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patentsSARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively. The two patents are directed to the gel formulation of the Bisphosphocin® Nu-3, which is being advanced into a Phase 2 clinical trial for the treatment of mildly infected diabetic foot ulcers (iDFU). The gel formulation of the topically applied Nu-3 is designed specifically to adhere to wounds and comprises lyotropic liquid crystals that form a mobile network through hydrogen bonding to water."These newly issued patents further strengthen and expand our global intellectual property portfolio surrounding the Bisphosphocin platform, which we believe is one of our company's most important strategic assets," said Kelvin Cooper, Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "As we advance the development of Nu-3 and our broader pipeline of novel antimicrobial compounds, expanding our worldwide patent estate remains central to protecting our innovation, enhancing future commercial opportunities, and creating long-term shareholder value. With almost 100 granted and pending patents, we believe Lakewood-Amedex Biotherapeutics is building a strong competitive position in the fight against antimicrobial resistance."New patents directed to Bisphosphocin gel formulations:On February 3, 2026, The Intellectual Property Office of New Zealand (IPONZ) granted patent number 759577, titled, "Bisphosphocin Gel Formulations and Uses Thereof."On March 19, 2026, IP Australia granted Patent Number 2024202211, titled, "Bisphosphocin Gel Formulations and Uses Thereof."These two new patents expand the number of granted patents for the Nu-3 gel formulation to 27 patents, covering the following geographical regions - United States, European Patent Office (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland), India, Japan, Hong Kong, Brazil, United Kingdom, New Zealand, and Australia.About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.About Nu-3
Nu-3 is Lakewood-Amedex Biotherapeutics Inc.'s lead product being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). Nu-3 belongs to a novel class of antimicrobials being developed by Lakewood-Amedex Biotherapeutics Inc. called the Bisphosphocin® class, which possess a unique mechanism of action that enables rapid elimination of a broad spectrum of bacteria, including resistant pathogens and biofilms. Data from initial exploratory clinical trials with Nu-3 using subclinical doses did not reveal any safety signals and showed a trend of positive antimicrobial response and improved wound healing. Based on these results, the Company plans to conduct an initial Phase 2a safety and dose response study of Nu-3 followed by a placebo-controlled Phase 2b dose comparative study. This study is also designed to determine the most appropriate administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers.Forward-Looking Statements
This press release may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause our Company's actual results to differ materially from historical experience and our present expectations or projections.Relying on such statements involves risk, uncertainty and assumptions. These statements are based on the current estimates and assumptions of the management of Lakewood-Amedex Biotherapeutics Inc. as of the date of this press release and are subject to uncertainty and changes. All statements obtained in this press release are made only as of the date of this press release and Lakewood-Amedex Biotherapeutics Inc. does not undertake any obligation to publicly update any forward-looking statements.Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.comMedia Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-expands-global-ip-portfolio-for-lead-candidate-nu-3-targeting-infected-diabetic-foot-ulcers-302782417.htmlSOURCE Lakewood-Amedex Biotherapeutics Inc. Original: Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
iHub News
2月前
Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT)May 18, 2026 11:20 AM
IH Market News Manufacturing progress, stability data, and formulation advances are moving Lakewood-Amedex’s lead antimicrobial candidate closer to Phase 2 testing in infected diabetic foot ulcers. Key Investor Takeaways The primary catalyst is positive Nu-3 data supporting advancement toward a planned Phase 2 clinical trial Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) reported manufacturing and formulation progress for its Bisphosphocin® antimicrobial platform The company completed multikilogram cGMP manufacturing runs for both Nu-3 drug substance and gel formulation Stability testing showed Nu-3 drug substance remained stable for at least five years, while the gel formulation demonstrated two-year stability Management highlighted broader future applications for the Bisphosphocin® platform beyond diabetic foot ulcers, including urinary tract and pulmonary infections Why LABT Stock Is in Focus Lakewood-Amedex Biotherapeutics announced positive development and manufacturing data for Nu-3, its lead antimicrobial candidate targeting mildly infected diabetic foot ulcers.According to the company, it completed several multikilogram manufacturing runs for members of the Bisphosphocin® class under current Good Manufacturing Practices guidelines.The company also said it successfully manufactured multikilogram quantities of the Nu-3 gel formulation suitable for use in future clinical trials.Management noted that process improvements reduced production costs while enhancing physical chemistry characteristics of the drug substance.“Lakewood-Amedex Biotherapeutics has worked diligently to optimize formulation and manufacturing processes required to produce both the Bisphosphocin® drug substances and drug products,” said Kelvin Cooper, Ph.D., Chief Executive Officer at Lakewood-Amedex Biotherapeutics.The company reported that stability testing showed the Nu-3 drug substance remained stable for at least five years, while the final gel formulation remained stable for at least two years.Lakewood-Amedex also stated that initial antimicrobial effectiveness testing showed undetectable bioburden levels without requiring additional preservatives.Nu-3 is designed as a topical antimicrobial treatment for infected diabetic foot ulcers with a goal of reducing antimicrobial resistance risks.According to the company, the Bisphosphocin® platform demonstrated the ability in vitro to rapidly eliminate bacteria through destabilization of bacterial cell membranes, including resistant strains such as MRSA and VRE. Why This Matters for Investors The announcement may be important for investors because it shifts focus from early-stage discovery toward operational readiness for later-stage clinical development.Manufacturing scalability, formulation stability, and cGMP production capabilities are often critical hurdles for clinical-stage biotechnology companies preparing for larger trials and eventual commercialization efforts.The extended stability profile may also support future supply chain flexibility and commercial manufacturing potential if clinical development progresses successfully.Beyond diabetic foot ulcers, management is also positioning the Bisphosphocin® platform as a broader antimicrobial technology with potential applications across additional infectious disease indications.That broader platform narrative could become increasingly relevant as investors continue monitoring antimicrobial resistance and demand for alternative anti-infective therapies.However, the company remains in the clinical development stage, and Nu-3 has not yet demonstrated efficacy in larger late-stage trials.Future regulatory outcomes, clinical results, safety performance, and commercialization execution remain key uncertainties. What to Watch Next Investors may monitor: Timing and initiation of the planned Phase 2a Nu-3 clinical trial Dose-response and safety data from upcoming studies Potential expansion into additional infectious disease indications Further manufacturing scale-up and commercialization readiness updates Regulatory interactions tied to Nu-3 development and trial progression Lakewood-Amedex Biotherapeutics stock price Original: Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT)
US Market News
2月前
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot UlcersMay 18, 2026 8:02 AM
PR Newswire (US) Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers (iDFU) designed to reduce the risk of antimicrobial resistance (AMR). The Company has conducted drug substance (the active ingredient) manufacturing process development for a few members of the Bisphosphocin® class and has completed several multikilogram scale under current Good Manufacturing Practices (cGMP) guidelines with high efficiency. In addition, process development advances have improved the cost of goods and have produced bulk drug substance with enhanced physical chemistry characteristics. The Company has also conducted drug product (the gel formulation) manufacturing process development and multikilogram quantities of the Nu-3 gel formulation have been manufactured under cGMP guidelines, and the product is suitable for use in clinical trials."Lakewood-Amedex Biotherapeutics has worked diligently to optimize formulation and manufacturing processes required to produce both the Bisphosphocin® drug substances and drug products," said Kelvin Cooper, Ph.D., Chief Executive Officer at Lakewood-Amedex Biotherapeutics. "The Bisphosphocin® class of compounds are modified nucleotide molecules with excellent aqueous solubility, potentially making them adaptable to a range of different drug product formulations and delivery methods, which could have significant potential in additional indications such as complicated urinary tract infection (cUTI) and pulmonary infections. We look forward to advancing the current Nu-3 gel formulation into a planned Phase 2 clinical trial targeting iDFU."In key stability testing, the Company has shown that the Nu-3 bulk drug substance material is stable for at least five years, and further examinations of the Nu-3 formulation have shown the drug product to be stable for at least two years. In addition, initial testing for bioburden (the presence of viable microorganisms) and antimicrobial effectiveness has demonstrated that the drug product has undetectable bioburden levels for at least two years and does not require additional preservatives to maintain antimicrobial effectiveness.The Bisphosphocin® class of compounds has been shown in vitro to rapidly kill bacteria through a pH and concentration dependent destabilization of the bacterial cell membrane. This mechanism of action offers the potential to reduce the threat posed by antibiotic-resistant bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), and others.About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.About Nu-3
Nu-3 is Lakewood-Amedex Biotherapeutics Inc.'s lead product being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). Nu-3 belongs to a novel class of antimicrobials being developed by Lakewood-Amedex Biotherapeutics Inc. called the Bisphosphocin® class, which possess a unique mechanism of action that enables rapid elimination of a broad spectrum of bacteria, including resistant pathogens and biofilms. Data from initial exploratory clinical trials with Nu-3 using subclinical doses did not reveal any safety signals and showed a trend of positive antimicrobial response and improved wound healing. Based on these results, the Company plans to conduct an initial Phase 2a safety and dose response study of Nu-3 followed by a placebo-controlled Phase 2b dose comparative study. This study is also designed to determine the most appropriate administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers.Forward-Looking Statements
This press release may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause our Company's actual results to differ materially from historical experience and our present expectations or projections.Relying on such statements involves risk, uncertainty and assumptions. These statements are based on the current estimates and assumptions of the management of Lakewood-Amedex Biotherapeutics Inc. as of the date of this press release and are subject to uncertainty and changes. All statements obtained in this press release are made only as of the date of this press release and Lakewood-Amedex Biotherapeutics Inc. does not undertake any obligation to publicly update any forward-looking statements.Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.comMedia Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-positive-data-for-the-advancement-of-lead-candidate-nu-3-in-infected-diabetic-foot-ulcers-302773810.htmlSOURCE Lakewood-Amedex Biotherapeutics Inc. Original: Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers